Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 231,975,550 papers from all fields of science
Search
Sign In
Create Free Account
Negative Contrast Agent
Contrast media that has a lower amplification and intensity than the surrounding tissue making the contrast look less opaque when seen in an x-ray.
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
New MRI contrast agents based on silicon nanotubes loaded with superparamagnetic iron oxide nanoparticles
R. Gonzalez-Rodriguez
,
P. Granitzer
,
K. Rumpf
,
J. Coffer
Royal Society Open Science
2018
Corpus ID: 52285108
This article describes the preparation and fundamental properties of a new possible material as a magnetic resonance imaging…
Expand
2013
2013
Visualization of bile movement using MRI spin-labeling technique: preliminary results.
W. Gonoi
,
M. Akahane
,
+4 authors
K. Ohtomo
AJR. American journal of roentgenology
2013
Corpus ID: 23945083
OBJECTIVE The purpose of this article is to noninvasively visualize intrabiliary bile movement using an MRI spin-labeling…
Expand
2011
2011
Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment
T. Yamashita
,
T. Takahara
,
+8 authors
Y. Imai
Japanese Journal of Radiology
2011
Corpus ID: 1902519
PurposeThe aim of this study was to assess the feasibility of using intravenously administered gadofosveset trisodium as a…
Expand
2011
2011
Combined application for positive and negative contrast agent in the hysterosalpingo contrast sonography
Cui Qiu-li
2011
Corpus ID: 76462706
Objective To assess the feasibility of combined application for positive contrast agents(SonoVue) and negative contrast agents…
Expand
2010
2010
Gadofosveset as a negative contrast agent for detecting metastatic axillary lymph nodes in breast cancer patients on diffusion and T2* weighted images - a proof of principle
M. Korteweg
,
T. Takahara
,
W. Mali
,
W. Veldhuis
2010
Corpus ID: 79128416
Introduction: Axillary lymph node status is the most important factor determining prognosis in breast cancer patients. Assessment…
Expand
2009
2009
Defining juxtapapillary diverticulum with 3D segmented trueFISP MRCP: comparison with conventional MRCP sequences with an oral negative contrast agent
S. Morita
,
E. Ueno
,
Ai Masukawa
,
Kazufumi Suzuki
,
H. Machida
,
M. Fujimura
Japanese Journal of Radiology
2009
Corpus ID: 29105934
PurposeTo compare three-dimensional segmented true fast imaging with steady-state precession magnetic resonance…
Expand
1995
1995
Dual contrast magnetic resonance imaging with combined use of positive and negative contrast agent in human hepatocellular carcinoma.
Yuji Suto
,
Y. Shimatani
British Journal of Radiology
1995
Corpus ID: 36244874
Dual contrast magnetic resonance imaging (DCMR) with combined use of a negative contrast medium, chondroitin sulfate iron colloid…
Expand
1993
1993
Abdominal MRI using a negative contrast agent.
T. Bach‐Gansmo
,
B. Dupas
,
M. Gayet-delacroix
,
M. Lambrechts
British Journal of Radiology
1993
Corpus ID: 28786145
A dose of 0.5 g of a negative oral contrast agent for labelling the bowel, was given to 40 patients in a clinical trial. Oral…
Expand
1993
1993
Ferrimagnetic susceptibility contrast agents.
T. Bach‐Gansmo
Acta radiologica. Supplementum
1993
Corpus ID: 38289570
Contrast agents based on superparamagnetic particles have been in clinical development for more than 5 years, and the complexity…
Expand
1983
1983
Computed air myelography of the lumbosacral spine.
Tan Ws
,
Dimitrios G. Spigos
,
N. Khine
AJNR. American journal of neuroradiology
1983
Corpus ID: 21069339
Plain computed tomography (CT) of the lumbosacral spine may be a reliable method for diagnosing herniated disk when abundant…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE